Guangdong Xinyaguang Cable
001382
Haimo Technologies Group Corp.
300084
Shaoyang Victor Hydraulics
301079
4
KLT
831689
5
Qingdao Tianneng Heavy Industries
300569
CN Stock MarketDetailed Quotes
688177 Bio-Thera Solutions,
- 19.69
- -0.54-2.67%
Market Closed Mar 21 15:00 CST
8.15BMarket Cap-21.59P/E (TTM)
20.39High19.64Low14.79KlotVolume20.23Open20.23Pre Close29.40MTurnover0.36%Turnover RatioLossP/E (Static)414.08MShares38.0652wk High9.62P/B8.15BFloat Cap17.7052wk Low24.28Limit Up414.08MShs Float78.00Historical High16.18Limit Down3.71%Amplitude17.09Historical Low--Dividend TTM19.87Avg Price8.75KlotAsk--Div YieldTTM100Lot Size5.49KlotBid
Bio-Thera Solutions, News
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Bio-Thera Solutions Obtains Acceptance of Marketing Authorization Application for Golimumab Injection
Further Weakness as Bio-Thera Solutions (SHSE:688177) Drops 4.4% This Week, Taking Five-year Losses to 61%
Biotech: Biotech 2024 Annual Results Report Announcement
Biotech 2024 Annual Results Report Announcement
Bio-Thera Solutions (688177.SH): net loss of 0.509 billion yuan for the year 2024.
On February 25, Gelonghui reported that Bio-Thera Solutions (688177.SH) disclosed its performance report for 2024. During the reporting period, the company achieved revenue of 0.743 billion yuan, a year-on-year increase of 5.44%; the net income attributable to the parent company was -0.509 billion yuan, and the net income attributable to the parent company after deducting non-recurring gains and losses was -0.554 billion yuan; the company's basic EPS was -1.23 yuan, and the weighted average return on net assets was -53.10%.
Bio-Thera Solutions Signs Licensing Deal With Accord Biopharma for Arthritis Injection
Bio-Thera Solutions Gets Clinical Trial Approval for Breast Cancer Treatment
The highest exceeds 0.16 billion USD! Bio-Thera Solutions' Innovative Drugs overseas authorization sees new Order again.
① As of now, Bio-Thera Solutions' Golimumab injection has completed Global Phase III clinical research and its market application has been accepted by the European EMA. ② Apart from the USA market, the exclusive licensing and commercialization rights for BAT2506 in Europe, Brazil, and the rest of the Americas have been secured by STADA and SteinCares respectively.
Express News | Accord Biopharma: Exclusive Commercialization and License Agreement With Bio-Thera Solutions for Bat2506
Express News | Bio-Thera Solutions - to Receive $21 Mln Upfront, up to $143.5 Mln in Milestones Under Agreement
Express News | Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement With Intas Pharmaceuticals for Bat2506, a Proposed Biosimilar Referencing Simponi® (Golimumab), in the United States of America
Bio-Thera Solutions (688177.SH): Signed a licensing and commercialization agreement with Intas.
On February 10, Gelonghui reported that Bio-Thera Solutions (688177.SH) announced that the company signed a licensing and commercialization agreement with Intas Pharmaceuticals Ltd. (referred to as "Intas"), granting Intas the paid exclusive commercialization rights for the company's BAT2506 (golimumab) injection in the USA market. Bio-Thera Solutions will be responsible for research and development, production, and commercial supply, while Intas will manage BAT2506 in the USA through its subsidiary Accord BioPharma Inc. (referred to as "Accord").
Bio-Thera Solutions (688177.SH): The notification of approval for the clinical trial of BAT1006 in combination with trastuzumab and chemotherapy for the treatment of breast cancer has been received.
On February 10, Glory Link reported that Bio-Thera Solutions (688177.SH) announced the recent receipt of the "Drug Clinical Trial Approval Notification" approved and issued by the National Medical Products Administration. The clinical trial application for the company's investigational pharmaceutical injectable BAT1006 in combination with trastuzumab and chemotherapy for the treatment of breast cancer has been approved.
Unpleasant Surprises Could Be In Store For Bio-Thera Solutions, Ltd.'s (SHSE:688177) Shares
Express News | Bio-Thera Solutions Announces Regulatory Filing Acceptance for Bat2506, a Proposed Biosimilar to Simponi®, in the European Union
Bio-Thera Solutions (688177.SH): Dongtai Qiheng has cumulatively reduced its shareholding by 0.93%.
On February 5, 2025, Bio-Thera Solutions (688177.SH) announced that it received a "Notice of Completion of Shareholding Plan and Reduction Results" and a "Simplified Equity Change Report" from its shareholders Dongtai Qiheng and Huitianzhe. In this shareholding reduction plan, Dongtai Qiheng reduced its shares through block trading by 3,848,770 shares, accounting for 0.93% of the total shares of the company, and did not reduce shares through centralized bidding. After this equity change, Dongtai Qiheng and its concerted party Huitianzhe together hold 20,704,000 shares of the company.
Bio-Thera Solutions (688177.SH): The marketing authorization application for BAT2506 (Golimumab injection) has been accepted by the EMA in Europe.
On January 24, Gelonghui reported that Bio-Thera Solutions (688177.SH) submitted a Biological Product marketing application for BAT2506 (Golimumab) injection to the European Medicines Agency (EMA), and recently received notification of acceptance from the EMA. The registration review cycle and evaluation results of BAT2506 (Golimumab) injection at the EMA still have uncertainties, and the acceptance of this pharmaceutical marketing application will not affect the company's recent performance.
Bio-Thera Solutions (688177.SH): Plans to sign a decoration electromechanical contract with related parties.
Gelonghui reported on January 24 that Bio-Thera Solutions (688177.SH) announced it plans to sign a "Decoration and Electromechanical Contract" with its related party, Shui Niu Architecture Engineering Co., Ltd. (referred to as "Shui Niu Architecture"), regarding the decoration and electromechanical installation of the Bio-Thera R&D Center and marketing headquarters (Building One), with a contract price of 9,815,804 RMB.
Biotech 2024 Annual Results Pre-loss Announcement